<DOC>
	<DOCNO>NCT02631577</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics immunogenicity induction treatment consist atezolizumab combination obinutuzumab plus lenalidomide patient relapse refractory follicular lymphoma ( FL ) , follow maintenance treatment atezolizumab plus obinutzumab plus lenalidomide patient achieve complete response ( CR ) , partial response ( PR ) , stable disease end induction .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy Atezolizumab Combination With Obinutuzumab Plus Lenalidomide Patients With Relapsed Refractory Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Relapsed refractory FL treatment least one prior chemoimmunotherapy regimen include antiCD20 monoclonal antibody appropriate treatment option exists determine investigator Histologically document CD20positive lymphoma determine local laboratory Fluorodeoxyglucoseavid lymphoma ( i.e. , PETpositive lymphoma ) At least one bidimensionally measurable lesion ( &gt; 1.5 cm large dimension CT scan magnetic resonance image [ MRI ] ) Availability representative tumor specimen correspond pathology report retrospective central confirmation diagnosis FL Agreement comply local requirement lenalidomide risk minimization plan For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use two adequate method contraception , include least one method failure rate &lt; 1 % per year , least 28 day prior Day 1 Cycle 1 , treatment period ( include period treatment interruption ) , least 18 month last dose study treatment For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure agreement refrain donate sperm least 3 month last dose study treatment Grade 3b follicular lymphoma History transformation indolent disease diffuse large Bcell lymphoma ( DLBCL ) Known CD20negative status relapse progression Central nervous system lymphoma leptomeningeal infiltration Prior allogeneic stemcell transplantation ( SCT ) Completion autologous SCT within 100 day prior Day ( D ) 1 Cycle ( C ) 1 Prior standard investigational anticancer therapy specify protocol History resistance lenalidomide response duration &lt; 1 year Treatment systemic immunosuppressive medication History solid organ transplantation Clinically significant toxicity prior therapy resolve Grade &lt; =2 ( accord National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] , v4.0 ) prior Day 1 Cycle 1 History erythema multiforme , Grade &gt; = 3 rash , blister follow prior treatment immunomodulatory derivative thalidomide lenalidomide Active bacterial , viral , fungal , infection Positive hepatitis B surface antigen ( HBsAg ) , total hepatitis B core antibody ( HBcAb ) , hepatitis C virus ( HCV ) antibody screen Known history HIV positive status History progressive multifocal leukoencephalopathy History autoimmune disease Contraindication treatment TE prophylaxis Grade &lt; = 2 neuropathy History malignancy could affect compliance protocol interpretation result Evidence significant , uncontrolled concomitant disease Inadequate hematologic function ( unless due underlie lymphoma ) Abnormal laboratory value ( unless due underlie lymphoma ) Pregnant lactate intend become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>